ClinicalTrials.gg
RecruitingNCT06630923Updated Oct 8, 2024

PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS

A Phase 3 interventional study of Human albumin in Diuretics Drug Reactions, Heart Failure; With Decompensation and Albumin; Double, sponsored by Democritus University of Thrace. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Democritus University of Thrace · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Heart Failure with a site in Greece — 21 open to participants now, 27 under way, 14 of them phase 3. Heart Failure · Greece.

Planned enrollment
53rd of 84
250 · median 367
Started
2023
with 1 other
Phase 3
35 of 105
12 open now
Primary completion
2025-12
later than 3 of 26 live
Registered
84th of 105
by date

Among the 105 studies in Heart Failure with a site in Greece, this one is the 53rd largest by planned enrollment of the 84 interventional ones that give a count, is one of 2 that started in 2023, is one of 35 in phase 3, reaches primary completion later than 3 of the 26 other live ones, and was the 84th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

21 of the 105 studies in Heart Failure with a site in Greece are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Heart Failure with a site in Greece, or all of them as a file.
02

Study summary

Patients hospitalized for acute decompensation of CHF are usually complicated by worsening renal function (WRF) which leads to diuretic resistance and inadequate decongestion as well as poor prognosis. WRF has been attributed to a reflex renal vasoconstriction elicited by intravascular volume depletion during brisk diuresis. The investigators hypothesize that CHF patients with hepatic dysfunction are more prone to WRF due to poor albumin production. This sub-group of CHF patients may benefit more (increased diuretic efficacy and protected against worsening renal function) by the use of IV loop diuretics in combination with an intravascular volume expander such as IV Human Albumin.

Read the detailed description

Acute decompensation of chronic heart failure (CHF) warranting hospital admission, defined as diagnosed on the basis of the presence of at least one symptom (dyspnea, orthopnea, paroxysmal nocturnal dyspnea, weight gain, worsening functional class or edema) and one sign (rales, peripheral edema, ascites, increased jugular vein pressure, hepatomegaly, third heart sound gallop or pulmonary vascular congestion on chest radiography) of heart failure plus laboratory or imaging evidence of hepatic dysfunction at randomization

03

Conditions studied

  • Diuretics Drug Reactions
  • Heart Failure; With Decompensation
  • Albumin; Double

Browse trials for

Keywords

  • Human Albumin
  • Furosemide
  • Heart Failure
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age over 18 yrs
  2. acute decompensation of CHF
  3. evidence of hepatic dysfunction by laboratory biochemical measurements or imaging (liver ultrasonography)
  4. history of CHF with previous use of an oral loop diuretic
  5. anticipated need for IV diuretic therapy for at least 72 hours

There is no pre-specified inclusion criterion with respect to

Exclusion criteria

Exclusion Criteria:

  1. hemodynamic collapse (at least one of the following: systolic blood pressure (BP) \< 90 mmHg, or BP drop by >= 40 mmHg for >= 15 min, with end-organ hypoperfusion; need for inotropes (except of digoxin); need for cardiopulmonary resuscitation).
  2. hepatic dysfunction of other than cardiac etiology
  3. severe anemia (\<8 g/dL)
  4. uncontrolled hypertension or hypertensive emergency/urgency
  5. pulmonary edema or pulmonary congestion necessitating use of IV vasodilators
  6. serum creatinine > 3 mg/dL or (GFR) \< 30 ml/min
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    IV Human Albumin + IV Furosemide

    Continuous slow IV infusion of Human Albumin plus IV Furosemide

    Drug: Human albumin

  • Placebo comparator
    IV Furosemide alone

    Continuous slow IV infusion of Furosemide

    Drug: Human albumin

Interventions

  • DrugAlbumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Experimental intervention (Group A): Continuous slow IV infusion of Human Albumin, based on diuresis-adjusted dosing, not later than 30 minutes after randomisation and not later than 2 hours after admission. Concomitant continuous slow IV infusion of diuretics (furosemide) based on body weight- and diuresis-adjusted dosing. Control intervention (Group B): Continuous slow IV infusion of diuretics (furosemide), based on body weight - and diuresis-adjusted dosing. Experimental intervention (Human Albumin) is off-label treatment for patients with acute decompensation of CHF in Greece. Control intervention (IV diuretic therapy) is on-label treatment for acute decompensation CHF in Greece.

06

What researchers measure

Primary outcomes

  1. Assessment of symptoms

    Patient's global assessment of symptoms, measured with the use of a visual-analogue scale (VAS) and quantified as the area under the curve (AUC) of serial assessments.

    Time frame: From baseline to 72 hours.

  2. Change in the serum creatinine level

    Change in the serum creatinine level

    Time frame: From baseline to 72 hours.

Secondary outcomes

  1. Patient-reported dyspnea

    Patient-reported dyspnea (as assessed with the use of a VAS and quantified as the AUC of serial assessments)

    Time frame: From baseline to 72 hours.

  2. Changes in body weight

    Changes in body weight

    Time frame: From baseline to 72 hours.

  3. Length of stay

    Length of stay

    Time frame: From baseline to discharge.

  4. The composite of death, rehospitalization, escalation in treatment or an emergency room visit within 180 days.

    The composite of death, rehospitalization, escalation in treatment or an emergency room visit within 180 days.

    Time frame: From baseline to 180 days from discharge.

  5. Net fluid loss

    Net fluid loss

    Time frame: From baseline to 72 hours

07

Study locations

1 of 1 sites recruiting
  • DUThrace Cardiology Department
    Alexandroupolis, Evros 68100, Greece
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 34 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Oct 8, 2024
StartActual
Jan 14, 2023
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 11, 2026
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06630923
Lead sponsor
Democritus University of Thrace
Responsible party
Marios-Vasileios Koutroulos (Cardiology Resident, Democritus University of Thrace) — Principal investigator
First posted
Oct 8, 2024
Start date
Jan 14, 2023
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 11, 2026 (estimated)
Last update
Oct 8, 2024

Study contacts

MARIOS-VASILEIOS A KOUTROULOS
Contact
mvkoutroulos@gmail.com
+30 6942862493
ANARGYROS TSALGKIDIS
Contact
anargyrost@gmail.com
6940926983
MARIOS VASILEIOS KOUTROULOS
principal investigator · University Hospital of Alexandroupolis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion